Search hospitals > New York > New York
Icahn School of Medicine at Mount Sinai
Claim this profileNew York, New York 10029
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Solid Tumors
Conducts research for Multiple Myeloma
1544 reported clinical trials
158 medical researchers
Summary
Icahn School of Medicine at Mount Sinai is a medical facility located in New York, New York. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Solid Tumors, Multiple Myeloma and other specialties. Icahn School of Medicine at Mount Sinai is involved with conducting 1,544 clinical trials across 1,428 conditions. There are 158 research doctors associated with this hospital, such as Edward J. Kim, Matthew Galsky, M.D., Deborah Doroshow, MD, PhD, and Thomas Marron, MD PhD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
CD20 positive
2Breast Cancer
Global LeaderStage IV
Stage III
HER2 negative
Top PIs
Edward J. KimUniversity of California Davis Comprehensive Cancer Center2 years of reported clinical research
Studies Pancreatic Cancer
Studies Liver Cancer
33 reported clinical trials
70 drugs studied
Matthew Galsky, M.D.Icahn School of Medicine at Mount Sinai5 years of reported clinical research
Studies Bladder Cancer
Studies Cancer
16 reported clinical trials
29 drugs studied
Deborah Doroshow, MD, PhDMount Sinai Hospital5 years of reported clinical research
Studies Cancer
Studies Solid Tumors
17 reported clinical trials
41 drugs studied
Thomas Marron, MD PhDIcahn School of Medicine at Mount Sinai1 year of reported clinical research
Studies Lung Cancer
Studies Solid Tumors
14 reported clinical trials
24 drugs studied
Clinical Trials running at Icahn School of Medicine at Mount Sinai
Breast Cancer
Crohn's Disease
Ovarian Cancer
Pompe Disease
Inflammatory Bowel Disease
Cancer
Prostate Cancer
Asthma
Ulcerative Colitis
Fallopian Tube Cancer
Ribociclib + Hormone Therapy
for Breast Cancer
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC).
Recruiting2 awards Phase 34 criteria
Elacestrant
for Breast Cancer
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
Recruiting2 awards Phase 33 criteria
Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib
for Breast Cancer
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
Recruiting2 awards Phase 312 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Icahn School of Medicine at Mount Sinai?
Icahn School of Medicine at Mount Sinai is a medical facility located in New York, New York. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Solid Tumors, Multiple Myeloma and other specialties. Icahn School of Medicine at Mount Sinai is involved with conducting 1,544 clinical trials across 1,428 conditions. There are 158 research doctors associated with this hospital, such as Edward J. Kim, Matthew Galsky, M.D., Deborah Doroshow, MD, PhD, and Thomas Marron, MD PhD.
Where is Icahn School of Medicine at Mount Sinai located?
The Icahn School of Medicine at Mount Sinai is situated in Manhattan, New York, nestled on the Upper East Side between Fifth and Madison Avenues, covering East 98th to 102nd Streets. Accessible by subway line number 6 and bus lines M1, M2, M3, M4, M96, M98, M101, M102, M103, M106. For comprehensive public transit details, visit the Metropolitan Transportation Authority (MTA) website.
Who should I call to ask about financial aid or insurance network?
**Financial Assistance at Icahn School of Medicine at Mount Sinai:**
- **Department of Patient Financial Services:** For financial assistance applications and eligibility inquiries, contact (212) 731-3100 or visit One Gustave L. Levy Place, Box 6000, New York, New York 10029.
**Insurance Inquiries:**
- **Customer Service Billing Office:** For insurance and billing questions, call (212) 987-3100, Monday-Friday, 8 am – 6 pm.
- **Mount Sinai Doctors Faculty Practice:** Participates in most insurance plans, including Medicare. Verify acceptance and discuss requirements by contacting the physician's office or your insurance company directly.
What insurance does Icahn School of Medicine at Mount Sinai accept?
The Icahn School of Medicine at Mount Sinai, part of the Mount Sinai Health System, participates in numerous health plan networks. It's important to verify that both the hospital and the physicians involved in your care accept your insurance plan. For detailed information on physician insurance participation, use the "Find a Doctor" feature at www.mountsinai.org, and for hospital-specific insurance information, direct inquiries to the respective departments or visit the hospital's website.
What awards or recognition has Icahn School of Medicine at Mount Sinai received?
The Icahn School of Medicine at Mount Sinai has been awarded a five-year, $55.5 million Clinical and Translational Science Award by the National Center for Advancing Translational Sciences, part of the NIH. This funding supports ConduITS, the Institute for Translational Sciences at Mount Sinai, enhancing its role in the CTSA Program, which includes 63 nationwide sites. It will boost Mount Sinai's capabilities in translational research informatics, digital health, and data science, accelerating research translation into discoveries for improved health outcomes across diverse populations.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.